Medtronic, a medical technology provider has entered into a new outcomes-based, risk-sharing agreement with Aetna for type 1 and type 2 diabetes patients currently on multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for a patient with diabetes who transition to Medtronic’s insulin pump therapy that constantly self-adjusts to keep patients’ blood sugar levels in range based on their personalized needs.
This outcomes-based, risk-sharing agreement continues to provide Aetna members’ access to Medtronic’s advanced diabetes technologies and comprehensive support services, including the new Minimed® 670G system.
The agreement ties a component of Medtronic’s reimbursement to successfully meeting agreed-upon clinical improvement thresholds for Aetna members with type 1 and type 2 diabetes who choose to transition from multiple daily injections to a Medtronic insulin pump, with the goal of elevating patient experience, improving clinical outcomes and lowering the total cost of care.
“This agreement reinforces our shift towards value-based healthcare. We know technology alone isn’t enough and ultimately, improved outcomes are what matter,” said Hooman Hakami, president of the Diabetes Group at Medtronic. “Our goal is to continue to lead by driving innovation that demonstrably improves patient outcomes, elevates patient experience and lowers the total cost of care. We have the only insulin delivery systems in the world that take action based on sensor values. The growing body of clinical evidence demonstrating the benefits of our proprietary SmartGuard(TM) Technology is compelling and we are pleased to work with Aetna to drive awareness and align incentives around the technologies that make the biggest difference for patients and for the health system.”